[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100314496":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":48,"locations":54,"responsibleParty":65,"collaborators":10,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":10,"enrollmentInfo":77,"targetDuration":80,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":10,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"iOMEDICO AG","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"aRCC",null,"Patients with advanced renal cell carcinoma",[13],"Other: Routine care as per site standard.",{"label":15,"type":10,"description":16,"interventionNames":17},"aUBC","Patients with advanced urothelial carcinoma (locally advanced and inoperable, or metastatic)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"High-risk MIUC","Patients with muscle-invasive urothelial carcinoma classified as high-risk after radical surgery (ypT2-ypT4 and\u002For ypN+,M0 for patients with prior neoadjuvant chemotherapy; pT3-pT4 and\u002For pN+, M0 for patients without prior neoadjuvant chemotherapy)",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"OTHER","Routine care as per site standard.","Physician's choice according to patient's needs.",[19,9,15],[29,33,36,39,42,45],{"name":30,"affiliation":31,"role":32},"Michael Staehler, Prof. Dr.","Ludwig Maximilian University of Munich, Dept. of Urology - University Hospital, Munich, Germany","STUDY_CHAIR",{"name":34,"affiliation":35,"role":32},"Peter Goebell, Prof. Dr.","University Clinic Erlangen, Department of Urology Comprehensive Cancer Center Erlangen EMN, Erlangen, Germany",{"name":37,"affiliation":38,"role":32},"Lothar Müller, Dr.","Onkologie UnterEms, Leer-Emden-Papenburg, Leer, Germany",{"name":40,"affiliation":41,"role":32},"Viktor Grünwald, Prof. Dr.","University Hospital Essen West German Cancer Center Essen, Clinic for Medical Oncology and Clinic for Urology, Essen, Germany",{"name":43,"affiliation":44,"role":32},"Carsten Grüllich, Prof. Dr.","Sana Clinic Hof, Dept. of Hematology and Oncology, Hof, Germany",{"name":46,"affiliation":47,"role":32},"Christian Gratzke, Prof. Dr.","University Hospital Freiburg, Dept. of Urology, Freiburg, Germany",[49],{"name":50,"role":51,"phone":52,"phoneExt":10,"email":53},"Michaela Koska","CONTACT","+49 761 15242-0","info@iomedico.de",[55],{"facility":56,"status":57,"city":58,"state":10,"zip":10,"country":59,"countryCode":60,"cosmosGeoPoint":10,"geoPoint":10,"contacts":61},"Multiple sites, Germany","RECRUITING","Multiple Locations","Germany","DE",[62],{"name":5,"role":51,"phone":63,"phoneExt":10,"email":64},"+49 761 152420","info@iomedico.com",{"type":66,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100314496","registry-platform-urologic-cancer-100314496",false,"NCT03374267","Registry Platform Urologic Cancer","Clinical Research Platform On Urologic Cancer Treatment And Outcome (Registry Platform Urologic Cancer; CARAT)","CARAT","Inclusion Criteria:\n\nCohorts aRCC and aUBC (prospective)\n\n* Female and male patients with aRCC or aUBC (locally advanced, inoperable or metastatic)\n* Patients at start of their first-line systemic treatment for aRCC or aUBC\n* Written informed consent\n\n  * Patients participating in the PRO module: signing of in-formed consent form and completion of baseline questionnaire before start of initial systemic treatment\n  * Patients not participating in the PRO module: within twelve weeks after start of systemic first-line for aRCC or aUBC\n* Age ≥ 18 years\n\nCohort High-risk MIUC (prospective and retrospective)\n\n* Histologically proven muscle-invasive urothelial carcinoma (MIUC) of the lower or upper urinary tract (ICD-10 C65, C66, C67.x, C68.x). Mixed histologies are allowed (main compo-nent must be urothelial carcinoma, with minor variants accept-ed).\n* Radical surgery (e.g., radical cystectomy, nephroureterecto-my) between October 1, 2021 and October 31, 2024.\n* High-risk of recurrence, defined as follows: Post-operative, pathological tumor status\n\n  * ypT2-ypT4 and\u002For ypN+ and without clinically detectable metastases (M0) at cystectomy for patients with prior neo-adjuvant chemotherapy or\n  * pT3-pT4 and\u002For pN+ and without clinically detectable me-tastases (M0) at cystectomy for patients without prior neo-adjuvant chemotherapy.\n* Age ≥ 18 years at the time of surgery.\n* Written informed consent (only if patient is alive at time of data entry; not applicable for inclusion of deceased patients' data)\n\nExclusion Criteria:\n\nCohorts aRCC and aUBC (prospective)\n\n* Patients with prior systemic therapy for aRCC or aUBC\n* No systemic treatment for aRCC or aUBC\n\nCohort High-risk MIUC (prospective and retrospective)\n\n* Partial cystectomy or partial nephrectomy of the primary tumor as definitive therapy\n* Metastatic disease (M1) at the time of surgery","ALL","18 Years",{"count":78,"type":79},1930,"ESTIMATED","3 Years","OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced renal cell carcinoma or urothelial cancer in Germany.",[84,85],"Renal Cell Carcinoma","Urothelial Carcinoma","2025-09-19",{"date":88,"type":89},"2025-09-22","ACTUAL",{"date":91,"type":89},"2017-12-07",{"date":93,"type":79},"2028-09",{"name":5,"class":6},1]